Skip to content Skip to footer
Subscribe Now
Viewpoints_Jonathan Rigby
VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease

In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn's disease and also highlighted about Janssen's efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared…
August 17, 2021

Read more

Viewpoints_Jan Wehkamp
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety & efficacy…
August 9, 2021

Read more